Strategies for management of the peritoneal surface component of cancer: cytoreductive surgery plus perioperative intraperitoneal chemotherapy.
BACKGROUND
A prominent part of treatment failure of gastrointestinal and gynecologic malignancy is dissemination to peritoneal surfaces. This has been associated with a limited survival and no reliable treatment strategies.


METHODS
A review of the natural history of carcinomatosis was performed and a rationale for intraperitoneal chemotherapy was sought. The pharmacology of chemotherapy administration into the peritoneal cavity was reviewed.


RESULTS
The technology of perioperative intraperitoneal chemotherapy requires the administration of drugs along with moderate hyperthermia in the operating room as a planned part of the surgical procedure. The solution in which the chemotherapy is diluted has an effect upon the drug clearance from the peritoneal cavity. Also, the volume of the carrier solution affects the exposure of cancer nodules on peritoneal surfaces .


CONCLUSIONS
New combinations of intraperitoneal chemotherapy administration when combined with optimal surgical technology for maximal chemotherapy effects should result in benefit to patients with peritoneal surface dissemination of gastrointestinal and gynecologic malignancy.
Sugarbaker
Paul H
PH
Washington Cancer Institute, Washington, DC 20010, USA. Paul.Sugarbaker@medstar.net
Stuart
O Anthony
OA
Yoo
Dal
D
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000493:pharmacokinetics / Q000627:therapeutic use; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D005833:Genital Neoplasms, Female / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D006979:Hyperthermia, Induced; D007263:Infusions, Parenteral; D007432:Intraoperative Period; D016685:Mitomycin / Q000493:pharmacokinetics / Q000627:therapeutic use; D010529:Peritoneal Cavity; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D011184:Postoperative Period
D000970:Antineoplastic Agents; D016685:Mitomycin; D004317:Doxorubicin; D005472:Fluorouracil